Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Equities research analysts at Wedbush issued their Q3 2024 earnings estimates for Ascendis Pharma A/S in a research note issued on Monday, November 4th. Wedbush analyst Y. Zhong forecasts that the biotechnology company will earn ($1.98) per share for the quarter. Wedbush currently has a "Strong-Buy" rating on the stock. The consensus estimate for Ascendis Pharma A/S's current full-year earnings is ($7.24) per share. Wedbush also issued estimates for Ascendis Pharma A/S's Q4 2024 earnings at ($1.71) EPS, FY2024 earnings at ($8.27) EPS, Q1 2025 earnings at ($1.86) EPS, Q2 2025 earnings at ($1.25) EPS, Q3 2025 earnings at ($1.01) EPS, Q4 2025 earnings at $1.25 EPS, FY2025 earnings at ($2.81) EPS, FY2026 earnings at $0.64 EPS, FY2027 earnings at $5.19 EPS and FY2028 earnings at $10.99 EPS.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million.
Other equities research analysts have also recently issued reports about the company. Wells Fargo & Company boosted their price target on Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an "overweight" rating in a research note on Tuesday, September 17th. Cantor Fitzgerald reiterated an "overweight" rating and set a $170.00 target price on shares of Ascendis Pharma A/S in a research report on Monday. TD Cowen raised their price target on Ascendis Pharma A/S from $157.00 to $160.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. Jefferies Financial Group upped their price objective on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a "buy" rating in a research report on Tuesday, August 13th. Finally, Oppenheimer reissued an "outperform" rating and issued a $190.00 target price (up from $180.00) on shares of Ascendis Pharma A/S in a report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $195.92.
Get Our Latest Analysis on Ascendis Pharma A/S
Ascendis Pharma A/S Stock Performance
NASDAQ:ASND traded down $2.81 during mid-day trading on Thursday, reaching $126.55. 266,595 shares of the company's stock were exchanged, compared to its average volume of 443,208. Ascendis Pharma A/S has a one year low of $86.54 and a one year high of $161.00. The business's fifty day simple moving average is $132.77 and its two-hundred day simple moving average is $133.34. The firm has a market capitalization of $7.67 billion, a PE ratio of -13.89 and a beta of 0.66.
Institutional Investors Weigh In On Ascendis Pharma A/S
A number of institutional investors have recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC lifted its holdings in shares of Ascendis Pharma A/S by 5.8% during the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company's stock worth $572,341,000 after purchasing an additional 229,995 shares during the period. Westfield Capital Management Co. LP grew its position in shares of Ascendis Pharma A/S by 1.1% in the 1st quarter. Westfield Capital Management Co. LP now owns 4,075,214 shares of the biotechnology company's stock valued at $616,050,000 after buying an additional 44,580 shares during the last quarter. Capital International Investors increased its stake in shares of Ascendis Pharma A/S by 0.5% in the first quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company's stock valued at $331,261,000 after buying an additional 10,044 shares during the period. Price T Rowe Associates Inc. MD raised its position in shares of Ascendis Pharma A/S by 23.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company's stock worth $269,374,000 after acquiring an additional 336,976 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its stake in shares of Ascendis Pharma A/S by 5.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 1,711,015 shares of the biotechnology company's stock worth $233,348,000 after acquiring an additional 93,185 shares during the period.
Ascendis Pharma A/S Company Profile
(
Get Free Report)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Read More
Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
